Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acapatamab - Amgen

Drug Profile

Acapatamab - Amgen

Alternative Names: AMG 160; anti-PSMAxanti-CD3-BiTE; anti-PSMAxanti-CD3-BiTE-bispecific-T-cell-engager

Latest Information Update: 15 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; BeiGene
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 07 Nov 2023 Amgen terminates a phase I/II trial in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in United Kingdom, Sweden, Spain, Australia, USA, Canada, Netherlands, Germany, Italy (IV) due to strategic reasons (NCT04631601)
  • 03 Jul 2023 Amgen completes a phase I trial in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in Austria, Belgium, Canada, France, Japan, the Netherlands, Singapore, the US and Taiwan (NCT03792841)
  • 27 Feb 2023 Phase-I clinical trials in Non-small cell lung cancer in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top